Ario Pharma (TRPV1 Antagonist Molecule) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Ario Pharma (TRPV1 Antagonist Molecule) General Information

Description

A series of small molecule TRPV1 antagonists in England, United Kingdom. The molecule asset includes the clinically ready and safe development candidate XEN-D0501.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Cambridge
  • England, United Kingdom
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Acquirer
Pila Pharma
Vertical(s)
TMT
Corporate Office
  • Cambridge
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ario Pharma (TRPV1 Antagonist Molecule) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ario Pharma (TRPV1 Antagonist Molecule)‘s full profile, request access.

Request a free trial

Ario Pharma (TRPV1 Antagonist Molecule) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ario Pharma (TRPV1 Antagonist Molecule)‘s full profile, request access.

Request a free trial

Ario Pharma (TRPV1 Antagonist Molecule) FAQs

  • Where is Ario Pharma (TRPV1 Antagonist Molecule) headquartered?

    Ario Pharma (TRPV1 Antagonist Molecule) is headquartered in Cambridge, United Kingdom.

  • What industry is Ario Pharma (TRPV1 Antagonist Molecule) in?

    Ario Pharma (TRPV1 Antagonist Molecule)’s primary industry is Buildings and Property.

  • Is Ario Pharma (TRPV1 Antagonist Molecule) a private or public company?

    Ario Pharma (TRPV1 Antagonist Molecule) is a Private company.

  • What is Ario Pharma (TRPV1 Antagonist Molecule)’s current revenue?

    The current revenue for Ario Pharma (TRPV1 Antagonist Molecule) is .

  • Who are Ario Pharma (TRPV1 Antagonist Molecule)’s investors?

    Ario Pharma has invested in Ario Pharma (TRPV1 Antagonist Molecule).

  • When was Ario Pharma (TRPV1 Antagonist Molecule) acquired?

    Ario Pharma (TRPV1 Antagonist Molecule) was acquired on 30-Mar-2016.

  • Who acquired Ario Pharma (TRPV1 Antagonist Molecule)?

    Ario Pharma (TRPV1 Antagonist Molecule) was acquired by Pila Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process